Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Inhibrx Biosciences (INBX) EBITDA Margin (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed EBITDA Margin for 3 consecutive years, with 2106.85% as the latest value for Q2 2025.

  • On a quarterly basis, EBITDA Margin rose 15879115.0% to 2106.85% in Q2 2025 year-over-year; TTM through Sep 2025 was 11949.57%, a 623864.0% increase, with the full-year FY2024 number at 165724.0%, down 15354506.0% from a year prior.
  • EBITDA Margin was 2106.85% for Q2 2025 at Inhibrx Biosciences, down from 1595.43% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 1595.43% in Q1 2025 to a low of 160898.0% in Q2 2024.
  • A 3-year average of 44098.65% and a median of 3616.18% in 2023 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: plummeted -4480248bps in 2024, then soared 15879115bps in 2025.
  • Inhibrx Biosciences' EBITDA Margin stood at 5125.52% in 2023, then plummeted by -874bps to 49928.0% in 2024, then skyrocketed by 96bps to 2106.85% in 2025.
  • Per Business Quant, the three most recent readings for INBX's EBITDA Margin are 2106.85% (Q2 2025), 1595.43% (Q1 2025), and 49928.0% (Q4 2024).